The aim of this study was evaluate the AURKA and AURKB mRNA expression profile of pediatric ALL patients, to construct a protein–protein interaction network to evaluate the possible role of those targets in leukemogenesis pathway and the efficacy of two designed aurora kinase inhibitors in a leukemia cell line as a potential novel treatment to ALL pediatric patients. The gene discussed is AURKA; the disease is acute lymphoblastic leukemia.